Actively Recruiting
Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer
Led by University of Texas Southwestern Medical Center · Updated on 2025-11-12
15
Participants Needed
1
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the impact of combining innate immune system activation (with IMSA101) with antigen release (through SAbR/PULSAR) on limited progressing lesions during ongoing adaptive immune system activation (with maintenance Nivo).
CONDITIONS
Official Title
Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must have metastatic clear cell renal cell carcinoma (ccRCC).
- Patients must have oligoprogression defined as progression in 5 or fewer lesions.
- All oligoprogression lesions must be suitable for radiation treatment.
- Patients must have at least one site of disease that can be safely injected with IMSA101.
- Karnofsky Performance Status (KPS) of at least 50%.
- Age 18 years or older.
- Patients must have adequate organ and marrow function within 14 days prior to study entry.
- All International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk categories are allowed.
You will not qualify if you...
- Patients with progressive ultracentral or central chest lesions are excluded.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75390
Actively Recruiting
Research Team
S
SARAH NEUFELD, MANAGER OF CLINICAL RESEARCH, MS, MBA
CONTACT
R
RAQUIBUL HANNAN, MD, PhD.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here